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Oncogenic transformation of postmitotic neurons triggers cell death, but the identity of genes critical for degeneration remain unclear.
The antitumor antibiotic mithramycin prolongs survival of mouse models of Huntington’s disease in vivo and inhibits oxidative stress-
induced death in cortical neurons in vitro. We had correlated protection by mithramycin with its ability to bind to GC-rich DNA and
globally displace Sp1 family transcription factors. To understand how antitumor drugs prevent neurodegeneration, here we use struc-
ture–activity relationships of mithramycin analogs to discover that selective DNA-binding inhibition of the drug is necessary for its
neuroprotective effect. We identify several genes (Myc, c-Src, Hif1, and p21waf1/cip1) involved in neoplastic transformation, whose
altered expression correlates with protective doses ofmithramycin or its analogs. Most interestingly, inhibition of one these genes, Myc,
is neuroprotective, whereas forced expression of Myc induces Rattus norvegicus neuronal cell death. These results support a model in
which cancer cell transformation shares key genetic components with neurodegeneration.
Introduction
Developmental and pathological cell deaths are highly regulated
decisions in postmitotic neurons. Among themolecules that have
been shown tomodulate neuronal loss in physiology and disease,
cell cycle mediators have garnered significant attention (Heintz,
1993; Freeman et al., 1994; Liu and Greene, 2001; Herrup, 2010).
Early studies involving the simian virus 40 T-antigen, which pro-
motes cell cycle progression via its ability to bind tumor suppres-
sors, showed that transformation is simultaneously sufficient to
drive transformation in dividing neuroblasts and, surprisingly,
cell death in postmitotic neurons (Park et al., 2007). Since then, a
role for cell cycle proteins in cell death in neurological disorders
has been confirmed, but key regulators regulating this transition
in postmitotic neurons are unknown, in part because of the ab-
sence of specific tools to elucidate the convergence between on-
cogenesis and neurodegeneration; such tools are essential
because transformation is likely not the product of a single gene but
rather a cooperative interactome culminating in amultifaceted phe-
notype (McMurray et al., 2008).
Over the past decade, the DNA binding drug mithramycin
(MTM) has emerged as a useful chemical tool for studying the
convergence between tumor transformation andneurodegenera-
tion. Fifty years ago, Curreri and Ansfield (1960) demonstrated
thatMTMproduced remissions in cases of embryonal carcinoma
and choriocarcinoma of the testis. In vitro footprinting studies
showed that MTM binds with highest affinity to GC-rich DNA
(VanDyke andDervan, 1983). Footprinting and gel shift analyses
were also used to show that MTM and Sp1 competitively bind to a
GC-richmotif in theMyc (Snyder et al., 1991) andc-Src (Remsing et
al., 2003) promoters. Indeed, the ability ofMTM to bind toGC-rich
DNA and displace the Sp1 family proteins from binding sites in
numerous genes has been amodel supported by100 publications.
Interest in understanding the mechanism of action of MTM
was further stimulated by two unexpected but converging pre-
clinical studies. Torrance et al. (2001) screened 30,000 com-
pounds and identified four, including MTM, that selectively
suppressed growth in DLD-1 colon cancer cells but left their
normal counterparts unaffected. The concentrations used matched
studies that showed that MTM completely suppressed apoptosis
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of neurons as a result of oxidative stress or DNA damage without
affecting global protein synthesis (Chatterjee et al., 2001). These
findings were consistent with a scheme in which oxidative stress
robustly induces DNA binding of Sp1 and Sp3 to affect proapo-
ptotic gene expression (Ryu et al., 2003). Support for the model
came from studies in which MTM improved behavior and ex-
tended the survival of Huntington’s disease (HD) mice signifi-
cantly (Ferrante et al., 2004; Voisine et al., 2007). Together, these
data show that nanomolar concentrations of MTM could sup-
press tumor growth, enhance neuronal survival, and have no
immediate effect on normal cell division.
We have used MTM analogs to probe transcriptional path-
ways necessary for oxidative neuronal death in vitro and in a fly
model of HD. Our studies indicate a remarkable convergence
between genes involved in transformation and those necessary
for some types of neurodegeneration.
Materials andMethods
Cell culture
Immature primary cortical neurons were obtained from fetal Sprague
Dawley rats [embryonic day 17 (E17)] as described previously (Ratan et
al., 1994). Transformed SH-SY5Y neuroblastoma cells were cultured
in DMEM/F-12 plus GlutaMAXmedium and 10% fetal bovine serum
(Invitrogen).
Drosophila stocks, crosses, and survival assay
The polyglutamine-expressing transgenic stock used in this study is w;
P{UAS-Httex1p Q93}4F1. These flies were mated with the pan-neuronal
elav driver w; P{wmW.hs  GawB}elavC155. Cultures were raised at
25°C. Virgin female progeny from the elav-Gal4 males  Httex1p Q93
females cross were collected and transferred to vials containing standard
Drosophila food supplemented with 10 M mithramycin A (MTM), 10 M
mithramycinSDK(SDK), 10MmithramycinSK(SK), 10Mpremithrmy-
cin B (PreB), and water. The survival of at least 30–100 animals was moni-
tored. In separate experiments, the fliesweredecapitated, and theheadswere
mounted on microscopic slides with nail polish after 10 d of feeding with
MTMand its analogs.The rhabdomereswereanalyzedunderoil emersionat
63 tovisualize individual rhabdomeres.The scoring (counting thenumber
of rhabdomeres per ommatidium) was done by a blinded investigator. Res-
cue was calculated compared with the control group by the formula 100 *
(RtRc)/7Rc,whereRc is thenumberof rhabdomeresperommatidium
in the control group andRt is the number of rhabdomeres per ommatidium
in the treatment groups. RNA was isolated from the Drosophila heads, and
expression of the mutant Huntington (mHtt) was assessed using re-
verse transcription-PCR followed by real-time PCR using the SYBR
GreenPCRMasterMix (AppliedBiosystems)and the followingprimerpairs
(huntingtin, 5-CCGCTCAGGTTCTGCTTTTA-3 and 5 AAGGACTT-
GAGGGACTCGAA-3; Act5C, 5-ATCATCGTTTTGGGCGCATG-3 and
5-CATAGTATATCAATATCATATCTCATG-3).
Cell viability
For cytotoxicity studies, immature primary cortical neurons (E17) were
isolated as described above and plated at a density of 106 cells/ml in
96-well plates. The next day, three sets of experiments were performed.
Cells were rinsed with warm PBS and then placed in medium containing
the glutamate analog homocysteic acid (HCA) (5 mM). HCAwas diluted
from100-fold concentrated solutions that were adjusted to pH7.5. In the
first set of experiments, increasing concentrations ofMTMor its analogs
(SDK, SK, and PreB) were added at the time of HCA treatment and were
present throughout the experiment.MTM and its analogs were prepared
as 10mM solutions, and serial dilutions were used to arrive to the desired
concentration. In the second set of experiments, MTM and its analogs
were added at various time points after HCA addition (0, 2, 3, 4, 5, 6, and
7 h after HCA addition). In the third set of experiments, 40 M Int–H1–
S6A F8 c-myc inhibitor (cell permeable; Enzo Life Sciences) (Giorello et
al., 1998) or the H1–S6A F8 c-myc inhibitor (non-cell-permeable nega-
tive control; Enzo Life Sciences) were added at the time of HCA treat-
ment and were present throughout the experiment. The next day, cell
viability was assessed by the MTT assay (Promega) (Mosmann, 1983).
One-way or two-way ANOVA followed by the Dunnett’s or Bonferroni’s
post hoc tests, respectively, were used to measure statistical significance.
p 0.05was considered to be statistically significant. The effectiveness of
the MTT assays in measuring cell viability was confirmed by using the
Live/Dead assay (Invitrogen) and fluorescence microscopy.
RNA extraction and real-time PCR
Total RNA was prepared from immature primary cortical neurons (E17)
using the NucleoSpin RNA II kit (MACHEREY-NAGEL) according to the
protocol of the manufacturer. Real-time PCRs were performed as a duplex
reaction using a Myc (Rn00561507_m1), p21waf1/cip1 (Rn01427989_s1),
c-Src (Rn01418228_m1), andHif1 (Rn00577560_m1) gene expression as-
say (Applied Biosystems), which use a 6-carboxyfluorescein-labeled probe,
and a -actin gene expression assay, which uses a VIC-labeled probe (Ap-
pliedBiosystems) so that gene amplification couldbenormalized to-actin.
These experiments were performed using a 7500 Real-time PCR System
(Applied Biosystems) using standard PCR protocol and amplification con-
ditions. One-way ANOVA followed by the Dunnett’s post hoc test were per-
formed to measure statistical significance. p  0.05 was considered to be
statistically significant.
Microarray analysis
Total RNA was extracted from immature primary cortical neurons
(E17), after 4 h treatments with HCA (5mM) along with protective doses
(300 nM MTM and 75 nM SDK) as well as non-protective doses (50 nM
MTMand 7.5 nM SDK) ofMTMand SDK. The PreB (300 nM) treatments
were used as negative controls. Three replicates were run per sample
category, for a total of 36 arrays. RNA quantity was assessed with Nano-
drop (Nanodrop Technologies) and quality with the Agilent Bioanalyzer
(Agilent Technologies). Total RNA (200 ng) was amplified, biotinylated,
and hybridized on Illumina Chips. Slides were scanned using Illumina
BeadStation and signal extracted using Illumina BeadStudio software.
Raw data was analyzed using Bioconductor packages. Quality assessment
was performed looking at the inter-array Pearson’s correlation, and clus-
tering based on top variant genes was used to assess overall data coher-
ence. Contrast analysis of differential expression was performed using
the LIMMA package (Smyth et al., 2005). After linear model fitting, a
Bayesian estimate of differential expression was calculated, and the
threshold for statistical significance was set at p  0.005. Data analysis
was aimed at assessing the effect of drug treatment on control cells and
cells treated with HCA. Gene Ontology (GO) analysis was performed
using DAVID (for Database for Annotation, Visualization, and Inte-
grated Discovery), and pathway analysis was performed by using the
Functional Analysis Annotation tool in the Ingenuity Pathways Analysis
software (Ingenuity Systems).
Weighted gene coexpression network analysis. The weighted gene coex-
pression network analysis was performed as described (Zhang and Hor-
vath, 2005; Oldham and Geschwind, 2006; Oldham et al., 2008). Briefly,
after selecting genes the 6000 most variant genes, the absolute Pearson’s
correlation coefficients between one gene and every other screened gene
were computed, weighted, and used to determine the topological overlap
(TO), a measure of connection strength, or “neighborhood sharing” in
the network. A pair of nodes in a network is said to have high TO if they
are both strongly connected to the same group of nodes. In gene net-
works, genes with high TO have been found to have an increased chance
of being part of the same tissue, cell type, or biological pathway.
Promoter analysis. Promoter analysis was performed using the Tran-
scription Analysis Listening System (TeLiS) (Cole et al., 2005). Of 4026
annotated probes, 1703 genes were found in the TeLiS database for pro-
moter analysis (42% of submitted). One hundred ninety-two transcrip-
tion factor binding motif matrices were scanned using TRANSFAC 3.2
[promoter size, 600 bases; high stringency (0.90)]. Of these matrices,
seven were significantly overrepresented at p  0.001 and a 2% false
discovery rate: Sp1 (two occurrences), GC box elements, AP2, ELK1
VMYB, ATF, and CREBP1 (Cole et al., 2005).
Promoter activity assays
Immature primary cortical neurons (E17) were transfected with the re-
porter expression vectors [p21::Luc, p21 (Sp1 mut)::Luc (Xiao et al.,
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1999), Myc::Luc (Chung et al., 2006), Myc (Del6)::Luc (kind gift from
Drs. David Levens and Hye-Jung Chung, National Cancer Institute,
Bethesda, MD), E-box::Luc (pMyc–TA–Luc; Clontech), and
control::Luc (pTA–Luc; Clontech) firefly luciferase plasmids using Lipo-
fectamine 2000 (Invitrogen)] in accordance with the protocols of the
manufacturers. The next day, cells were treated with MTM (300 nM),
SDK (75 nM), SK (300 nM), PreB (75 and 300 nM), or Int–H1–S6A F8
c-myc inhibitor (40M) overnight. Next, the cells were washed with PBS
and then lysed with luciferase assay buffer (Promega). The protein con-
centration was measured using a protein assay kit (Bio-Rad). Firefly
luciferase activities were measured using a luciferase reporter assay
system (Promega) and an LMax II 384 luminometer (Molecular De-
vices). Firefly luciferase values were standardized to total protein
concentration.
Immunoblot analysis
Nuclear and cytoplasmic protein extracts were obtained using NE-PER
Nuclear and Cytoplasmic Extraction Reagents (Pierce Biotechnology) in
the presence of protease inhibitors, the proteasome inhibitor MG-132,
and phosphatase inhibitors according to the protocol of the manufac-
turer. Samples were boiled in Laemli’s buffer and electrophoresed under
reducing conditions on NuPAGE Novex 4–12% Bis-Tris Gel polyacryl-
amide gels (Invitrogen). Proteins were transferred to a nitrocellulose
membrane (Bio-Rad) by electroblotting. Nonspecific binding was inhib-
ited by incubation in Odyssey blocking buffer (LI-COR Biosciences).
Antibodies against Sp1 (PEP2; Santa Cruz Biotechnology), c-Myc
(1472-1; Epitomics), p21waf1/cip1 (OP-76; Calbiochem), and -actin
(AC-74; Sigma-Aldrich) were diluted 1:1000, 1:1000; 1:1000, and
1:10,000, respectively, in Odyssey blocking buffer, and the membranes
were incubated overnight at 4°C. Fluorophore-conjugated Odyssey
IRDye-680 or IRDye-800 secondary antibody (LI-COR Biosciences) was
used at 1:10,000 dilution followed by incubation for 1 h at room temper-
ature. Finally, proteins were detected using an Odyssey infrared imaging
system (LI-COR Biosciences).
Chromatin immunoprecipitation
The Ez-Magna ChIP assay kit was used as directed by the manufacturer
(Millipore). Briefly, primary cortical cells were crosslinked with 1% formal-
dehyde at 37°C for 7 min. Cells were then sonicated using the Bioruptor
(Diagenode)and immunoprecipitatedwithprimaryantibodies (10g).The
crosslinking was reversed, and the DNA was isolated on the columns pro-
vided by the kit. Shearing size was determined to be between 150 and 1000
bp. Real-time PCR was conducted with primers targeted to the Myc
promoter (rat promoter primers pair, 5-GAGCGAGAGGAGGAAA-
AAAATAGA-3 and 5-CAGACCCCCGGATTATAAAGG-3) or the
p21waf1/cip1 promoter (rat promoter primer pair, 5-CCGATGCTATAA-
GACCGCAGATCT-3 and 5-CAATTCCCCTTAACTCGGGCACTG-
TAGCAGCTC-3) andSYBRGreenPCRMastermix (AppliedBiosystems).
Each experiment was conducted at least three times by crosslinking cells
from different primary cortical neuron preparations.
Myc short hairpin RNA knockdown
Two Myc (NM_012603) short hairpin RNA (shRNA) clones
(TRCN0000039641, 5 AAACCCAGGGCTGCCTTGGAAAAG 3 and
TRCN0000039641, 5 AAACCCAGGGCTGCCTTGGAAAAG 3; Open
Biosystems) and Non-Target shRNA Control Vector (Sigma) were intro-
duced into immature primary cortical neurons (E17) using the Amaxa Rat
NeuronNucleofector kit as directed by themanufacturer (Lonza). The next
day, Myc knockdown was confirmed by whole-cell lysate Western blots. In
addition, cells were treated with 5 mM HCA overnight, and viability was
assessed using theMTT assay.
Figure 1. A, MTM and analog chemical structures.B, Description of MTM analog structure, DNA binding ability, inhibition of Sp1 and Sp3 function, and role in carcinogenesis comparedwith the
parent MTM compound.
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Adenoviral infections
Immature (E17) rat primary cortical cells were infected with 80 multi-
plicity of infection of a Myc adenovirus (kind gift fromDrs. Preeti Ahuja
andRobbMacLellan,University ofCaliforniaLosAngeles, LosAngeles,CA)
or enhanced green fluorescent protein (GFP) adenovirus for 2 h in HBSS,
after which the normal growth media were restored. The next day, Myc
overexpression was confirmed by whole-cell lysate Western blots. In addi-
tion, cells were treated with either HCA (5mM) alone or with both HCA (5
mM) andMTM (300 nM).
Statistical analysis
One-way or two-way ANOVA followed by the
Dunnett’s or Bonferroni’s post hoc tests, re-
spectively, were used to measure statistical sig-
nificance. p  0.05 was considered to be
statistically significant.
Results
MTM and its analogs increase the
lifespan of an HDmodel of
Drosophila melanogaster
HD is a dominantly inherited neurode-
generative disorder. It is caused by expan-
sion of a polyglutamine tract in Htt. Like
other neurodegenerative disorders, HD is
characterized by oxidative stress, DNA
damage, and apoptosis. Previously, we
have shown that MTM is one of the most
effective compounds in ameliorating the
phenotypes in the R6/2 mouse model of
HD (Ferrante et al., 2004). These findings
have been replicated in other laboratories
(Stack et al., 2007), but the limited avail-
ability of the drug and its potential toxicity
have precluded its testing in HD patients.
Our goal in the current study was to use the
MTM chemical analogs (SDK, SK, and
PreB) (Fig. 1) to (1) better understand the
mechanism of action of MTM, (2) to iden-
tify a source of MTM analogs that could al-
low scalable production for humanuse, and
(3) to identify compounds that are at least as
efficacious as MTM but that have a higher
threshold for toxicity.
Tobegin to address these questions in an
in vivo context, we examined the efficacy of
MTMand its analogs in aDrosophilamodel
ofHD.Thebasic structureofMTMis thatof
a tricyclic chromophore with a unique hy-
drophilic side chain attached in 3-position.
MTM analogs SDK and SK are obtained by
targeted gene inactivation of enzymes in-
volved in the biosynthetic pathway of
MTM, differ from the parent compound
only in the structure and length of the hy-
drophilic side chain, andexhibit lowerDNA
binding affinity (Fig. 1). In contrast, PreB
has four rings compared with three in
MTM, lacks the hydrophilic 3-side chain,
and is unable to bind to DNA (Remsing et
al., 2003). To determine whether the MTM
analogs can extend lifespan of flies express-
ingmHtt inneurons in vivo aswell asMTM,
we examined the effect of MTM and the
MTM analogs (SDK, SK, and PreB) on the
lifespan of transgenic flies expressing Htt
exon 1 containing 93 glutamines (Q93) in all neurons. Normally,
these flies exhibit motor defects and have a median survival of 9.5 d
(Fig. 2A). As expected, flies fedwithMTM(10M) had an extended
median survival of 13 d, a lifespan extension comparable with the
most effective treatments tested in this model. Similarly, flies fed
with both SDK (10M) and SK (10M)had an extended survival of
13 and 12.5 d, respectively. Moreover, feeding ofMTM and its ana-
Figure 2. MTM and its analogs SDK and SK are protective in a Drosophila melanogastermodel of HD. A, MTM or its analogs SDK
and SK significantly extend the lifespan of HD flies expressing exon 1 of Htt with 93 CAG repeats (Q93). Themedian survival of flies
receiving no treatment was 9.5 d compared with 13 d for flies receiving 10MMTM or SDK in their food or 12 d for flies receiving
10 M SK in their food. For the MTM and SDK feeding survival curves, p  0.0001 was calculated by the Mantel–Cox and
Gehan–Beslow–Wilcoxon tests, whereas for the SK feeding survival curves, p 0.001 or p 0.0005 were calculated by the
Mantel–CoxandGehan–Beslow–Wilcoxon tests, respectively. Feedingof PreB (10M)hadno statistically significant effect on the
survival of the HD flies. Themedian survival of these flies was 10 d. These results indicate that the DNA binding ability of MTM and
its analogs is necessary for their protective effect in vivo. B, MTM and its analogs had no significant effect on mHtt transgene
expression as measured by real-time PCR. This indicates that the protective effect of MTM, SDK, and SK is independent of modu-
lation of mHtt levels in the flies. C,D, MTM (10M), SDK (10M), and SK (10M) feeding enhanced the number of rhabdomeres
per ommatidium inHD flies comparedwith ones receiving no treatment. Rescuewas calculated at 40, 45, and 81% comparedwith
the control group by the formula 100 * (Rt Rc)/7 Rc, where Rc is the number of rhabdomeres per ommatidium in the control
group, and Rt is the number of rhabdomeres per ommatidium in the treatment groups. PreB (10M) feeding did not ameliorate
the loss of rhabdomeres per ommatidium observed in the HD Q93 flies, indicating that the DNA binding ability of MTM and its
analogs is necessary to suppress the neurodegeneration observed in the eyes of the HD flies. ***p 0.0001.
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logs (SDKand SK) enhanced the number of
rhabdomeres per ommatidium in HD flies
and protected against degeneration of the
eye. Rescue byMTM, SDK, and SKwas cal-
culated at 40, 45, and 81%, respectively,
compared with flies receiving no treatment
(Fig. 2C,D). Interestingly, feeding HD flies
withPreB (10M)didnot extend their lifes-
pan, nor did it rescue eye degeneration (Fig.
2A,C,D). The distinct effects of MTM ana-
logscouldnotbeattributed to their ability to
differentially affect mutant Htt transgene
expression levels (Fig. 2B). These results
suggest that MTM analogs can be effective
therapeutic agents in a fly model of HD.
They also demonstrate a structure–activity
relationship (SAR) with MTM, SDK, and
SKbeingequally effective inprolonging sur-
vival, whereas SK is superior in stemming
eye degeneration, and PreB being indistin-
guishable from control.
The SAR for MTM or its analogs in vivo
in affecting survival in a fly model of
HD is similar to their SAR affecting
oxidative death in cortical neurons in
vitro
The in vivo data suggest a SAR that can be
used to further elucidate the targets of
MTM. However, they do not exclude the
possibility that differences in the efficacies
of MTM analogs reflect pharmacokinetic
properties of the compounds or, alterna-
tively, deleterious effects in non-neuronal
cells that compromise overall efficacy.
Furthermore, we examined all of the
MTM analogs at a single dose. To further
refine our understanding of the SAR of
MTM and its analogs in neurodegenera-
tion, we used an in vitromodel of neuronal
oxidative death. Early in their develop-
ment in culture, cortical neurons exposed
continuously to glutamate (or a glutamate
analog, e.g., HCA) succumb through a
mechanism dependent on competitive in-
hibition of cystine transport (Ratan et al.,
1994). Reduced intracellular cyst(e)ine leads to depletion of the
antioxidant glutathione. Cell death attributable to glutathione
depletion has features of apoptosis and can be completely pre-
vented by classical antioxidants (Ratan et al., 1994). Because ox-
idative stress resulting from impaired cysteine uptake and in
turn glutathione depletion is a putative mediator of dysfunction
and death in HD (140Q/140Q) mice (Li et al., 2010) as well as in
a host of other acute and chronic neurodegenerative conditions
and because many agents protective in our in vitro model are
effective in rodent HDmodels, we used this model to explore the
SAR of MTM analogs identified in HD flies. We treated primary
cortical neurons withHCA (5mM) alone or with varying concen-
trations of MTM, SDK, SK, and PreB and then quantified cell
death using MTT reduction and Live/Dead staining. We ob-
served that, likeMTM, both SK and SDK potently protect imma-
ture neurons from oxidative stress-induced cell death (Fig. 3).
The increased potency of SDK in protecting postmitotic neurons
correlates with its rapid uptake (Albertini et al., 2006) and in-
creased potency in killing of SH-SY5Y neuroblastoma cells (Fig.
4). In contrast, and consistent with the relative DNA binding
affinity and cellular uptake in cancer cells (Albertini et al., 2006), SK
exhibited the same potency as MTM in neurons. However, unlike
MTM, SK did not lead to significant loss in viability in cells not
undergoing oxidative stress. Moreover, in accordance with the fly
studies, PreB did not protect the neurons from oxidative stress-
induced cell death. Together, these findings suggest that the SAR for
MTManalogs defined in flies could be related to distinct differences
in the cell-autonomous mechanism of action of these drugs in de-
generating postmitotic neurons (Chatterjee et al., 2001). The lack of
a perfect congruence in SAR between the fly model in vivo and the
neuron in vitro systems is likely related to the fact that exquisitely
detailed concentration–response curves were generated in vitro,
whereas only a limited number of doses were tested in the flymodel
and the pharmacodynamics is likely different in vivo.
Figure3. MTM,SK, andSDKprotect immatureprimary cortical neurons (E17) fromoxidative stress in aDNAbinding-dependent
manner. A, MTM, SK, and SDK abrogate neuronal cell death induced by HCA (5 mM) in a dose-dependent manner. SDK was
protective at lower doses comparedwithMTMand SK. In addition, SK and SDK treatment induced no significant toxicity compared
withnon-HCAcontrol,whereasMTMtreatmentdid. *, Significantdeath comparedwithnon-HCAcontrol; **, significantprotection
comparedwith HCA treatment alone. PreB did not protect primary neurons fromHCA-induced cell death.B, Live/Dead staining of
treated neuron cultures. Live cells are identified by green, whereas dead cells are identified by red fluorescence.
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To harness the distinct effects of the analogs on protection
from oxidative death for better understanding of the mechanism
of action ofMTM,we next focused on determining the kinetics of
MTM protection from oxidative death. We reasoned that the
optimal time to analyze gene changes induced by MTM, SDK,
and SK that are relevant to their respective biological effects
would require an understanding of the latest time the drugs can
be added and still protect 100% of neurons. To determine the
“commitment point,” we exposed cells to HCA and then added
MTM, SK, or SDK at different time points.We observed a decline
in protection from 100%when the analogs were added5 h after
exposure to HCA (Fig. 5). Because MTM diffuses rapidly into
cells to bind to DNA (Albertini et al., 2006), we believe that the
commitment point reflects the actual time after which MTM
ceases to affect viability. From this, we conclude that 5 h is the
point after which MTM or its analogs cease to be effective in
stemming the apoptotic response; as a result, any transcriptional
responses observed beyond this time point are likely contami-
nated by secondary changes rather than a primary result ofMTM
or analog treatment. Accordingly, we performed a gene microar-
ray 4 h after exposure to HCA with or without protective or
nonprotective doses of the analogs.
A battery of genes covaries with protective doses of MTM and
its analogs versus nonprotective doses
To identify the transcriptional networks associated with protection
byMTMand its effective analogs,weused Illuminaarray technology
to simultaneously query 20,000 reference–sequence-curated
transcripts. As an initial step, we compared the levels of gene
expression from neuronal cells treated with protective doses of
MTM (300 nM) or SDK (75 nM) versus nonprotective doses (50
nM MTM or 7.5 nM SDK) or versus HCA (5 mM) alone. We also
examined gene expression from cells treated with the non-
neuroprotective analog PreB (300 nM) as an additional control.
As expected, treatment with effective doses of MTM and SDK
induced robust changes in gene expression, whereas nonprotec-
tive doses induced little or no change in gene expression at the
chosen statistical threshold ( p 0.005) (Fig. 6A). Differentially
expressed (DE) genes after treatment with MTM and SDK were
highly overlapping (84% of the DE genes after MTM treatment
are also DE after SDK treatment), supporting the idea that these
two compounds act on the same pathways (Fig. 6B). GO analysis
showed over-representation of a number of functional catego-
ries, including apoptosis, mitochondria, protein dimerization,
and S-adenosyl-methionine-dependent methyltransferase activ-
ity. Pathway analysis confirmed those categories and suggested a
main effect on transcriptional regulation. Interestingly, one of
the networks identified by our pathway analysis was centered on
Myc (Fig. 6C), which is downregulated by protective doses of
MTM and SDK and unaffected by the nonprotective doses or
PreB at both the mRNA and protein levels (Fig. 7C,G).
To dissect the transcriptional changes induced by protective
MTM and SDK treatment and to prioritize candidates for addi-
tional study, we performed an unbiased network analysis (Old-
ham et al., 2008) of the microarray expression profiles, which
allows groups of tightly coexpressed genes (modules) to be iden-
tified across many experimental conditions. Because genes ex-
pressed by the same cells or involved in similar functions are
often closely coexpressed in modules, large datasets enable such
gene groups to be identified (Oldham et al., 2008). Three main
modules showed strong correlation with MTM and SDK treat-
Figure 4. MTM and its analogs SK and SDK protect primary neurons from oxidative
stress when administered up to several hours after HCA (5 mM) treatment. MTM (300 nM)
significantly protects neurons from oxidative stress when administered up to 7 h after HCA
treatment, whereas the SK (300 nM) and SDK (75 nM) analogs continue to significantly
protect up to 5 h after HCA treatment. Statistical analysis was conducted by one-way
ANOVA followed by the Dunnett’s post hoc test. Significant protection compared with HCA
treatment alone: *p  0.05, **p  0.01, and ***p  0.0001. Untreated controls are
calculated at 100% survival.
Figure 5. Doses of MTM and its analogs (SDK and SK) that promote protection in immature
primary cortical neurons induce cell death in transformed SH-SY5Y neuroblastoma cells. As
expected, SDKwasmoreeffective in inducing cell death thanMTMor SK. PreBdidnot induce cell
death in neuroblastoma cells, further suggesting that the DNA binding ability of these com-
pounds is necessary for their function. **p 0.01; ***p 0.0001.
Sleiman et al. •Mithramycin Links Cancer and Neurodegeneration J. Neurosci., May 4, 2011 • 31(18):6858–6870 • 6863
ment. Although partially overlapping, the
GO analysis of these modules showed
somedistinctive features, suggesting over-
representation of mitochondrial, neuro-
genesis, and apoptosis genes, respectively.
For example, members of the mitogen-
activated protein kinase pathway, includ-
ing Raf1, Mek, and Erk1/2, were clustered
in these threemodules. Interestingly, Myc
(oncogene), Mycn (oncogene), Src (on-
cogene), and Hif1 (increased in many
cancers) were all clustered in a single
module. We confirmed by quantitative
real-time PCR that c-Src, Hif1, andMyc
were significantly downregulated by pro-
tective doses but unaffected by nonpro-
tective doses of MTM/SDK/SK or PreB
(Fig. 7A–C). c-Src has the ability to induce
Myc expression (Chang et al., 2008).
Hif-1 has been postulated to associate
with Myc to repress DNA repair genes,
thus enhancing mutations in genetic
hotspots (Yoo et al., 2009). This is inter-
esting considering that DNA repair is
among the top categories affected by
MTM and SDK treatment. Of note,
p21waf1/cip1 expression is increased by
MTM and SDK treatment. Real-time
PCR and Western blots confirmed that
its mRNA and protein levels are in-
creased (Fig. 7D,H ). Previous studies
from our laboratory and others have
shown that c-Src inhibition (Khanna et
al., 2002), Hif-1 deletion (Aminova et
al., 2008), or p21waf1/cip1 overexpression
(Langley et al., 2008) can protect neu-
rons from oxidative death, but the SAR
combined with the array are consistent
with a model whereby oxidative stress
requires the expression of genes in-
volved in oncogenic transformation to
mediate their deleterious effects on via-
bility or lifespan.
To understand whether there is com-
mon promoter architecture for those genes
that are downregulated that might explain
their sensitivity to MTM or its analogs, we
used the Telis database (www.telis.ucla.
edu), which looks for overrepresentation
of transcription factor binding sites in the
promoters of genes in DE gene lists. We
applied this analysis on the subset of
probes affected by both MTM and SDK
(n  4026). The top overrepresented
Figure 6. A network of genes centered on Myc covaries with MTM-mediated neuroprotection in immature primary cortical
neurons (E17).A, Protective doses ofMTM (300 nM) and SDK (75 nM) induce significant changes in gene expression comparedwith
4
HCA (5mM) alone orwith nonprotective doses ofMTM (50 nM),
SDK (7.5 nM), or PreB (300 nM). Cells were treated with the
compounds for 4 h. B, DE genes are highly overlapping after
treatmentwith protective doses ofMTMand SDK. C, Ingenuity
analysis reveals a network of genes centered on Myc and
whose expression covaries with protection by MTM and its
analogs.
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transcription factor was Sp1 (present in 50% of 1703 annotated
genes vs. 40% in the control set; p 1.00e-10). Nearly all of the
genes that are downregulated contain phylogenetically conserved
Sp1 consensus sites in their promoters. In contrast, p21waf1/cip1, a
tumor suppressor gene, alsohasphylogenetically conservedSp1 sites
in its promoter, and yet its expression was increased. The
remarkable ability of MTM or its bioactive analogs to reduce
the expression in neurons of genes associated traditionally
with oncogenesis and yet to increase the expression of a tumor
suppressor gene, p21waf1/cip1, led us to directly examine the
binding of Sp1 family members to distinct promoters of genes
suppressed or enhanced by MTM or its analogs.
Mithramycin and its analogs only partially mediate their
neuroprotective effect by inhibiting Sp1 family binding to
target genes
MTM is believed to be a canonical inhibitor of Sp family mem-
bers binding to their consensus DNA binding sites. To determine
whether the protective effects of MTM and its analogs covary
relative to their ability to inhibit Sp1 binding to target sites in the
promoters of genes identified in our informatics analysis, we per-
formed chromatin immunoprecipitation (ChIP) using both Sp1
and Sp3 antibodies. We chose Sp1 and Sp3 because we have
shown previously by electrophoretic mobility shift assay (EMSA)
that their DNA binding is robustly induced by oxidative stress in
cortical neurons (Ryu et al., 2003). We also chose these two fac-
tors because their DNA binding domains are virtually identical
(Fig. 8A,B). Based on the accepted mode of action of MTM, it
should inhibit both of these proteins to a similar extent. For the
ChIP assays, we focused on well-defined Sp1 consensus motifs in
the Myc (Snyder et al., 1991) and p21waf1/cip1 (Xiao et al., 1999)
promoters because nearly complete downregulation of Myc (on-
cogene) and upregulation of p21waf1/cip1 (tumor suppressor
gene) occurred at protective concentrations of all the analogs.We
validated these Sp1 consensus motifs in the Myc and p21waf1/cip1
promoters by conducting promoter reporter analysis. As ex-
pected, MTM, SDK, and SK, but not PreB, inhibited the expres-
sion of luciferase driven by the Myc promoter (Fig. 7E). In
contrast, MTM, SDK, and SK, but not PreB, induced the expres-
sion of a luciferase driven by the proximal p21waf1/cip1 promoter
(Fig. 7F). In each case, induction or repressionwas dependent on
the presence of the Sp1 sites. These findings focused our ChIP
experiments on those regions of theMyc or p21waf1/cip1 promoter
with Sp1 sites necessary forMTM-mediated repression or induc-
tion. We exposed cortical neurons to oxidative stress with pro-
tective or nonprotective doses ofMTMor SDK as well as with the
nonprotective PreB and then conducted the ChIP experiments at
the Myc or p21waf1/cip1 loci. Protective doses of MTM or SDK
significantly inhibited Sp1 occupancy at the Myc promoter,
whereas nonprotective doses had no effect (Fig. 8D). As expected,
treatment of cellswithPreBhadno effect onSp1binding;moreover,
the MTM/SDK-dependent decrease in Sp1 occupancy on the Myc
promoter was not attributable to an effect of MTM/SDK treatment
on Sp1 protein levels (Fig. 8C). Sp3 was also bound to the Myc
promoter. Surprisingly, MTM or SDK at protective or nonprotec-
tive doses failed to displace Sp3 from its site on the Myc promoter
(Fig.8E).Together, these studies showthatprotectivedosesofMTM
analogs inhibit Sp1, but not Sp3, occupancy at the proximal Myc
promoter and argue against the previously held model that MTM
binds to the minor groove of GC-rich DNA to displace the zinc
finger DNA binding domain of Sp1 family transcription factors. In-
deed, our data suggest that other factors outside of theDNAbinding
domain of Sp1 or Sp3 must explain the selectivity of MTM or its
analogs in inhibitingSp1,butnotSp3,binding todistinctpromoters.
Because MTM or its analogs increase the expression of
p21waf1/cip1, we examined the effect of MTM and SDK treatment
of cortical neurons exposed to oxidative stress on Sp1 and Sp3
occupancy of the p21waf1/cip1 promoter. As expected from our
gene expression and protein data, we observed thatMTM and SDK
had no effect on both Sp1 and Sp3 occupancy at the p21waf1/cip1
promoter (Fig. 8F,G). These results are the first demonstration
that MTM and its analogs do not uniformly inhibit Sp1 family
binding to target sites in promoters. Indeed, in previous EMSAs,
we found that MTM inhibited both Sp1 and Sp3 binding to a
consensus DNA binding sequence (Chatterjee et al., 2001). These
results suggest a model in which MTM inhibits Sp1 binding to a
Figure 7. Expression of genes involved in carcinogenesis covaries with protective doses of
MTM, SK, and SDK in immature cortical neurons (E17). Protective doses of MTM, SK, and SDK
significantly inhibit expression of c-Src, Hif1, andMyc (A–C) and upregulate the expression of
p21waf1/cip1 within 4 h (D). PreB has no effect. Significant protection comparedwith HCA treat-
ment alone: *p 0.05, **p 0.01, and ***p 0.0001. E, MTM (300 nM), SDK (75 nM), and SK
(300 nM) significantly inhibit the expression of full-length Myc promoter driving luciferase as
well as a deletion fragment that lost the five Sp1 binding sites upstream of the SmaI site at
101 relative to P1 promoter and that retains the Sp1 site between P1 and P2 promoter that
we studied in our ChIP experiments, indicating thatMTMand its analogsmediate their function
through these sites. PreB (300 nM) did not have any effect on any of the constructs. Untreated
controls are calculated at 100% luciferase activity. F, MTM (300 nM), SDK (75 nM), and SK (300
nM) significantly induce the expression of a 60 bp p21 cip1/waf1 promoter driving luciferase.
Conversely, mutating the Sp1 binding sites present in this construct abolishes the induction by
MTMand its analogs, indicating thatMTMand its analogsmediate their function through these
sites. PreB (300 nM) did not have any effect on any of the constructs. Statistical analysis was
conducted by one-way ANOVA followed by the Dunnett’s post hoc test. Significant protection
comparedwith the respective control: *p 0.05, **p 0.01, and ***p 0.0001. Untreated
controls are calculated at 100% luciferase activity. G, MTM (300 nM) treatment significantly
reduced the Myc protein levels. H, MTM (300 nM) treatment significantly induced p21waf1/cip1
protein levels.
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subset of genes associated with oncogenesis
but leaves Sp3 unperturbed. In contrast,
MTM has no effect of Sp1 binding to one
tumor suppressor; again Sp3 is unper-
turbed. To exclude the possibility that our
ChIP results reflect nonspecific cross-
reactivity of our antibodies with other pro-
teins,we reduced the expressionof bothSp1
andSp3 and thenperformedChIPs.Weob-
served a significant reduction in Sp1 and
Sp3 occupancy on the Myc and p21waf1/cip1
promoters compared with control condi-
tions, thusverifying the specificityofouran-
tibodies (data not shown).
Mithramycin and its analogs only
partially mediate their neuroprotective
effect by inhibitingMyc expression
Our findings pointed toMTM-specific re-
ductions in a gene network associated
withMyc oncogenesis (Fig. 6C). To estab-
lish whether the decreased expression of
the Myc gene in response to MTM and its
analogs can contribute to a protective
phenotype in neurons, we used an estab-
lished peptide inhibitor to reduce Myc
function. The Int–H1–S6A F8 c-myc in-
hibitor is cell permeable, affects Myc/Max
dimer formation, and inhibits Myc-
dependent transcription (Giorello et al.,
1998). As such, both MTM and the Int–
H1–S6A F8 c-myc inhibitor significantly
affect the expression of an E-box driving
luciferase (Fig. 9A). As expected, the Int–
H1–S6A F8 c-myc inhibitor partially pro-
tects immature primary cortical neurons
from oxidative stress-induced cell death,
whereas a nonpermeable negative con-
trol peptide (H1–S6A F8 c-myc inhibi-
tor) had no effect on oxidative stress-
induced neuronal cell death (Fig.
9B,C). To further verify the specificity
of our peptide inhibitor, we directly re-
ducedMyc expression using shRNA. Se-
lective reduction in Myc (Fig. 9D)
significantly protects immature cortical
neurons fromoxidative death (Fig. 9E). In
contrast, overexpression ofMyc in imma-
ture cortical neurons (Fig. 9F) signifi-
cantly reduced the survival of these cells (Fig. 9G), although it did
not sensitize them to oxidative death (Fig. 9E). In addition, Myc
overexpression did not abolish the protective effect of MTM.
A distinctive feature ofMyc is that it encodes two translational
forms, Myc1 and Myc2, that differ at their N terminal. Myc1 is
generated by a non-AUG translational start site. There is evidence
showing that Myc1 andMyc2 are functionally distinct (Hann et al.,
1994). Although in these experiments, we overexpressed the Myc2
translational isoform of the MYC gene, overexpression of Myc1
yields a similar outcome (datanot shown).These results suggest that
downregulation of Myc is sufficient, but not necessary, for the pro-
tective response inducedbyMTM.Altogether, these studies support
the notion thatMTM-mediated repressionof expressionof a host of
genes associated with oncogenesis, including Myc, Src, and Hif-1,
canprotectpostmitoticneurons fromoxidativedeath (Fig. 9H,I). Fur-
thermore,a strikingcorrelationexistsbetweenprotectivedosesof struc-
turally diverse MTM analogs and the reduction of expression of these
genes. Although the simple model has been that MTM inhibits Sp1
binding to many GC-rich binding sites in promoters, our findings
suggests that the protective effects of MTM in neurons derive from
reduction in Sp1 binding to a small set of promoters of genes whose
expression is classically associatedwith oncogenesis (Table 1) and its
ability to selectively ignoreSp1binding sites inotherpromoters such
as p21cip1/waf1 that are classically linked with tumor suppression.
Discussion
MTM is a prototypic Sp1 inhibitor that was engaged as a chemo-
therapeutic agent and found to have efficacy long before its
Figure 8. Protective doses of MTM and SDK inhibit Sp1 binding to a subset of its targets but have no effect on Sp3 binding. A,
Schematic depicting protein structures of Sp1 and Sp3. The glutamine-rich regions, serine/threonine regions, and the zinc fingers
that make up the DNA binding domain (DBD) are depicted by dark gray, light gray, and black boxes, respectively. The region
(/) is rich in chargedaminoacids. The four regions (A, B, C, andD) contribute to the transcriptional activity. Activationdomains
(AD) and inhibitory domains (ID) are shown. B, Protein sequence alignment of the DNA binding domain of Sp1 and Sp3. Cysteine
and histidine residues that coordinate zinc ions are highlighted in light gray, and protein regions that contact the DNA are
highlighted in dark gray. C, MTM (300 nM) treatment does not affect Sp1 protein levels in immature cortical (E17) neurons. D, E,
Protective doses ofMTMand SDK inhibit Sp1, but not Sp3, binding to their sites in theMyc promoter, whereas nonprotective doses
or PreB do not. F, G, MTM and SDK do not inhibit Sp1 or Sp3 binding to their sites in the p21waf1/cip1 promoter. Immature cortical
neurons (E17) were treated with the compounds for 4 h for both the Western blots and chromatin immunoprecipitation experi-
ments. Statistical analysis was conducted by one-way ANOVA followed by the Dunnett’s post hoc test. Significant protection
compared with the respective control: *p 0.05. Untreated controls are calculated at onefold.
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putative mechanism of action was understood. Using various
methods, several groups developed a model whereby MTM dis-
places Sp1 from its sites in aberrantly expressed oncogenes such
as Myc to mediate its antitumor actions. Here, we provide data
using careful SAR analysis of MTM analogs in vitro and in vivo
along with promoter analysis and chromatin immunoprecipita-
tions to support aspects of the previous model in an unexpected
context, neurodegeneration. Indeed, we have found thatMTMdis-
places Sp1 from its sites in the promoters of
select oncogenes such asMyc (Fig. 8D) and
that the reduction in expression of such
genes not only covaries with biological phe-
notype of neuroprotection in neurons (Fig.
6A,C, 7C) but also inhibition of each of
these targets individually [Myc (Fig.
9B,C,E), c-Src (Sen et al., 2000; Khanna et
al., 2002, 2006), Erk (Stanciu et al., 2000),
and Raf (Chin et al., 2004)] protects neu-
rons. Interestingly, althoughoxidative stress
does not increase Myc protein levels, we
speculate that it may induce a posttransla-
tional change in the Myc protein that alters
its ability to bindDNAor its transactivation
potential (data not shown). Additionally,
our analysis also provides unexpected in-
sights that may require a complete refine-
ment in our understanding of the mode of
action ofMTM. First,MTMfails to displace
Sp1 or Sp3 from all promoters in neurons
(Fig. 8E–G). This suggests that MTMmust
interactwithDNAinamanner that allows it
to selectively displace Sp1 from some sites
andnot others.Wehave found that Sp1 lev-
els are much lower than Sp3 levels, so the
differences may simply relate to differences
in capacity or affinity of Sp3 versus Sp1, a
feature not easily queried using ChIP analy-
sis. It is also possible that adjacent sequences
in the promoters play an important role
in establishing whether MTM can com-
petitively inhibit Sp1 occupancy. The con-
centration dependence of protection and
reductions ingeneexpressionorDNAbind-
ing does suggest a simple competitive inter-
action between Sp1 andMTM.
MTM was identified in a screen for
compounds effective in inhibiting tumor
cell growth without affecting normal cells
(Torrance et al., 2001). It is also one of the
most effective agents tested to date in a
worm model (Voisine et al., 2007) and
mousemodel (Chatterjee et al., 2001; Fer-
rante et al., 2004; Qiu et al., 2006; Ryu et
al., 2006) of HD. Moreover, MTM pro-
tects against dopaminergic neurotoxicity
in themouse brain after administration of
methamphetamine, suggesting that itmay
be effective in treatingmethamphetamine
users (Hagiwara et al., 2009). Together,
these studies highlight its potential thera-
peutic potential for many cancers as well
as CNS diseases characterized by neuro-
degeneration or acute insults. Indeed,
MTM is approved by the Food and Drug Administration for
leukemia and testicular cancer treatment; however, the side ef-
fects associatedwith its administration in humans have limited its
use. Translation of MTM to the bedside will be facilitated by the
development of analogs that are less toxic and more efficacious.
These analogs should also be available in quantities sufficient to
ultimately complete a human clinical trial. We chose to charac-
Figure9. Myc suppression is sufficient but not necessary tomediate the protective effects ofMTM in immature cortical neurons
exposed to oxidative stress. A, Protective doses of both MTM (300 nM) and Int–H1–S6A F8 c-myc inhibitor (40M) significantly
inhibit the expressionof an E-boxdriving luciferase construct (Clontech). ***p0.0001.B, Treatmentwith Int–H1–S6AF8 c-myc
inhibitor (40M) significantly protects cells from oxidative stress-induced death. The negative control peptide (H1–S6A F8 c-myc
inhibitor, 40 M) has no effect. *p 0.05. C, Live/Dead staining of treated neurons. D, Western blots showing a significant
reduction in Myc protein levels in cells expressingMyc shRNA compared with control shRNA. E, Inhibition of Myc expression using
shRNA protects immature primary cortical neurons (E17) from oxidative stress-induced death. *p  0.05. F, Western blots
showing that Myc protein is increased in immature primary cortical neurons (E17) infected with the Myc2 adenovirus. G, Overex-
pression of Myc2 in immature primary cortical neurons (E17) significantly affects their survival but is not sufficient to block the
ability of MTM to protect them from oxidative stress. Statistical analysis was conducted by one-way ANOVA followed by the
Dunnett’s post hoc test. Significant protection compared with control cells infected with Adeno-GFP: **p 0.01 and ***p
0.0001.H, Table highlighting themultiple signalingmolecules targeted by protective doses of MTM and its analogs and shown to
modulate neuroprotection in our model of oxidative stress. I, Model depicting pathways affecting oxidative death in neurons and
that are targeted by MTM, SDK, and SK. Expression of genes depicted in green is reduced, whereas expression of genes
depicted in red is induced by protective doses of MTM.
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terize two previously identifiedMTM analogs (SDK and SK) that
are obtained by genetic manipulation of the MTM biosynthetic
pathway because they have improved transcriptional and anti-
proliferative activity in cancer cell lines (Fig. 1) with minimal
effects on normal cell growth (Albertini et al., 2006) as well as in
human ovarian xenogafts in vivo (Previdi et al., 2010). Although
SDK and SK have a lower DNA binding affinity than the parent
compound, the doses of SDK and SK required for the inhibition
of tumor growth in orthotopic xenografts and for mice survival
were lower than those required for MTM (Previdi et al., 2010).
This could be in part attributable to their increased cellular up-
take andbioavailability (Albertini et al., 2006);moreover,no toxicity
was associated with SDK and SK treatment in vivo (Previdi et al.,
2010).We found that they, likeMTM,areprotective ina flymodelof
HD(Fig. 2) aswell as in a neuronalmodel of oxidative stress (Fig. 3).
Because of their reduced toxicity, we speculate that their use may
help circumvent the side effects of MTM.
We have identified a battery of genes that are regulated in
response to protective doses of MTM (Figs. 6, 7). During exam-
ination of the top networks, we observe that a subset of these
genes mediate cancer-related processes and that inhibition of at
least one of them, namely Myc, is sufficient to protect against
oxidative stress (Fig. 9B,C,E). Indeed, mice exclusively overex-
pressing Myc in neurons exhibit a neurodegenerative phenotype
(Lee et al., 2009); in addition, Myc overexpression in neurons is
sufficient to induce significant cell death (Fig. 9F,G). We specu-
late that, when cells are challenged with oxidative stress, onco-
genic signaling pathways become critical mediators of the
apoptotic response and that MTM functions to prevent these
pathways from tipping the balance toward death (Fig. 9I). We
find that MTM and its analogs target several key pathways (Erk,
c-Src, Hif1, and p21waf1/cip1) involved in carcinogenesis and
previously described to affect oxidative stress-mediated neuronal
cell death (Fig. 9H, I) (Sen et al., 2000; Khanna et al., 2002; Chin
et al., 2004; Aminova et al., 2008; Langley et al., 2008; Siddiq et al.,
2009). Indeed, the list of compounds that are effective in inhib-
iting both cancer cell growth and protecting neurons is growing
and includes histone deacetylase inhibitors (Sleiman et al., 2009),
mammalian target of rapamycin inhibitors (Ravikumar et al.,
2004; Shor et al., 2009), and transglutaminase inhibitors (Cac-
camo et al., 2010; McConoughey et al., 2010).
In agreement with our results, previous studies reveal that
MTM extends the survival of the R6/2 HD mice by normalizing
the expression of a subset the genes dysregulated in the presence
ofmHtt (Stack et al., 2007), and careful analysis of this list reveals
that all of these genes are involved in carcinogenesis. Indeed, an
increasing body of evidence from cell culture studies and post-
mortem tissue fromhuman disease hint at amechanistic connec-
Table 1. List of genes that are downregulated by protective doses of MTM (300 nM)
and SDK (75 nM), involved in carcinogenesis, and obtained from two networks
identified in themicroarray analysis: cell cycle andmolecular mechanism of cancer
Gene Mediate carcinogenesis
ADCY3 
ADCY8 
ADCY9 
BMPR1A 
HIF1A 
LRP5 
LRP6 
MAP2K4 
MAPK14 
NFKBIB 
PIK3C3 
PRKAG2 
RAP1B 
RRAS2 
SMAD1 
SMAD6 
SRC 
TCF3 
AATF 
ACVR1 
BCAR3 
CCNH 
CCT2 
CDC2A 
CHES1 
CRK 
CRKL 
CSPG6 
CTCF 
CUL1 
CUL3 
DLG7 
DNAJA2 
DNM2 
FOXG1 
FRAP1 
GSPT1 
ID3 
JAK2 
MAP2K1 
MAP2K6 
MAPK1 
MYC 
PBEF1 
PCNA 
RAF1 
RALBP1 
RUVBL1 
SIAH1A 
STRN3 
TNFSF5IP1 
TPX2 
TSG101 
TUBB3 
NOTCH1 
SMAD2 
SMAD4 
BCCIP 
BRINP2 
COMMD5 
DAB2IP 
DLGH1 
GAK 
(Table continues.)
Table 1. Continued
Gene Mediate carcinogenesis
LZTS1 
MAPK6 
MSH2 
PTEN 
RAD1 
RAP1A 
RB1 
SMPD3 
TBRG1 
UBE1C 
The majority of these downregulated genes normally promote carcinogenesis as opposed to a small number that
inhibit carcinogenesis.
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tion between oncogenic pathways and neurodegeneration/acute
insults to the CNS. For example, ectopic expression of oncogenes
such as simian virus 40 T antigen in Purkinje neurons induces
their degeneration (Feddersen et al., 1992).Moreover, expression
of cell cycle markers is induced in postmitotic neurons in re-
sponse to spinal cord injury (Di Giovanni et al., 2003), in striatal
neurons in response to excitotoxic injury (Liang et al., 2005), and
in neurodegenerative diseases such as Alzheimer’s disease (AD)
(Herrup et al., 2004; Yang and Herrup, 2007), and inhibition of
cyclin-dependent kinases blocks this neuronal cell death (Park et
al., 1997, 1998; Giardina and Beart, 2002; Rideout et al., 2003).
Additionally, dysregulation of multiple genes that mediate post-
mitotic degeneration is also observed in carcinogenesis (St-
aropoli, 2008). For example, mutations in the tumor suppressor
Park2 lead to cancer and Parkinson’s disease (Mehdi et al., 2010;
Poulogiannis et al., 2010; Tay et al., 2010; Veeriah et al., 2010).
Loss-of-function mutations in ataxia telangiectasia gene, ATM,
lead to degeneration of the nigrostriatal neurons (Eilam et al.,
1998, 2003) and increase the risk of breast cancer and leukemia
(Morrell et al., 1986; Thompson et al., 2005a,b), whereas gain-of-
function mutations in the amyloid precursor protein (APP) lead
to rare forms of AD as well as leukemia (Baldus et al., 2004). In
addition to APP, multiple oncogenic pathways known to be in-
volved in the G1 transition, such as Cdc42/Rac (Zhu et al., 2000)
and retinoblastoma p130 (Previll et al., 2007), contribute to AD.
Our findings suggest that MTM functions at the crossroad
between transformation and neurodegeneration, fit the notion
that transformation in cancer andneurodegeneration share path-
ways, and are in agreement with the proposed notion that, in
postmitotic neurons, clonal expansion has been supplanted by
clonal deletion to avoid tumors fromdeveloping all over the CNS
during aging (Heintz, 1993). In conclusion, it would be of interest
to determine whether aging or disease creates mutation hotspots
in oncogenes that would drive the neurons toward death.
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